Ciaran Skerry1, Michael L Pinn1, Natalie Bruiners2, Richard Pine2, Maria L Gennaro2, Petros C Karakousis3. 1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Public Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ, USA. 3. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA petros@jhmi.edu.
Abstract
BACKGROUND: The need to develop new, improved treatments for tuberculosis (TB) remains urgent, and the repurposing of existing drugs represents a possible shortcut to market. Recently, there has been significant interest in host-directed adjuvant therapy to enhance bacillary killing. HMG-CoA reductase inhibitors (statins), which are among the most commonly prescribed drugs, have immunomodulatory properties and improve the clinical outcomes of bacterial infections. METHODS: We studied the tuberculocidal activity of simvastatin alone and in combination with first-line anti-TB drugs in J774 macrophages and during chronic TB infection. RESULTS: Exposure to 5 μM simvastatin significantly increased the tuberculocidal activity of isoniazid in J774 macrophages at Day 3 after infection versus isoniazid alone (P=0.02). Similarly, relative to the standard oral regimen of rifampicin (10 mg/kg), isoniazid (10 mg/kg) and pyrazinamide (150 mg/kg) given five times weekly, the addition of 25 mg/kg simvastatin enhanced bacillary killing, reducing the number of lung cfu by an additional 1 log10 at Day 28 (P<0.01) and by a further 1.25 log10 at Day 56 (P<0.01). CONCLUSIONS: The potential additive activity of simvastatin to first-line TB treatment holds promise. However, further studies to identify the optimal statin and dosing are required. In addition the ability of combination treatment with statins to accelerate the time required to achieve a stable cure remains to be explored.
BACKGROUND: The need to develop new, improved treatments for tuberculosis (TB) remains urgent, and the repurposing of existing drugs represents a possible shortcut to market. Recently, there has been significant interest in host-directed adjuvant therapy to enhance bacillary killing. HMG-CoA reductase inhibitors (statins), which are among the most commonly prescribed drugs, have immunomodulatory properties and improve the clinical outcomes of bacterial infections. METHODS: We studied the tuberculocidal activity of simvastatin alone and in combination with first-line anti-TB drugs in J774 macrophages and during chronic TB infection. RESULTS: Exposure to 5 μM simvastatin significantly increased the tuberculocidal activity of isoniazid in J774 macrophages at Day 3 after infection versus isoniazid alone (P=0.02). Similarly, relative to the standard oral regimen of rifampicin (10 mg/kg), isoniazid (10 mg/kg) and pyrazinamide (150 mg/kg) given five times weekly, the addition of 25 mg/kg simvastatin enhanced bacillary killing, reducing the number of lung cfu by an additional 1 log10 at Day 28 (P<0.01) and by a further 1.25 log10 at Day 56 (P<0.01). CONCLUSIONS: The potential additive activity of simvastatin to first-line TB treatment holds promise. However, further studies to identify the optimal statin and dosing are required. In addition the ability of combination treatment with statins to accelerate the time required to achieve a stable cure remains to be explored.
Authors: Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191
Authors: Hendrik Schmidt; Ralf Hennen; Alexander Keller; Martin Russ; Ursula Müller-Werdan; Karl Werdan; Michael Buerke Journal: Intensive Care Med Date: 2006-06-21 Impact factor: 17.440
Authors: Zahoor Ahmad; Mostafa M Fraig; Michael L Pinn; Sandeep Tyagi; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis Journal: J Antimicrob Chemother Date: 2011-05-20 Impact factor: 5.790
Authors: Leena Erkkilä; Matti Jauhiainen; Kirsi Laitinen; Kristiina Haasio; Terttu Tiirola; Pekka Saikku; Maija Leinonen Journal: Antimicrob Agents Chemother Date: 2005-09 Impact factor: 5.191
Authors: Imad M Tleyjeh; Tarek Kashour; Fayaz A Hakim; Valerie A Zimmerman; Patricia J Erwin; Alex J Sutton; Talal Ibrahim Journal: Arch Intern Med Date: 2009-10-12
Authors: Min-Chul Kim; Sung-Cheol Yun; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim Journal: Am J Trop Med Hyg Date: 2019-08 Impact factor: 2.345
Authors: Noton K Dutta; Natalie Bruiners; Michael L Pinn; Matthew D Zimmerman; Brendan Prideaux; Véronique Dartois; Maria L Gennaro; Petros C Karakousis Journal: J Antimicrob Chemother Date: 2016-02-21 Impact factor: 5.790